دورية أكاديمية

Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer

التفاصيل البيبلوغرافية
العنوان: Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer
المؤلفون: Naoya Nishioka, Junji Uchino, Soichi Hirai, Yuki Katayama, Akihiro Yoshimura, Naoko Okura, Keiko Tanimura, Sachi Harita, Tatsuya Imabayashi, Yusuke Chihara, Nobuyo Tamiya, Yoshiko Kaneko, Tadaaki Yamada, Koichi Takayama
المصدر: Journal of Clinical Medicine; Volume 8; Issue 4; Pages: 450
بيانات النشر: Multidisciplinary Digital Publishing Institute
سنة النشر: 2019
المجموعة: MDPI Open Access Publishing
مصطلحات موضوعية: sarcopenia, non-small cell lung cancer, psoas major muscle area, red blood cell distribution width
الوصف: Secondary sarcopenia is defined as a decrease in muscle mass due to disease or malnutrition. Several studies have reported that secondary sarcopenia is an indicator of postoperative recurrence. We hypothesized that there is a correlation between the effect of immune checkpoint inhibitors (ICIs) and sarcopenia. We retrospectively analyzed 38 patients with advanced non-small cell lung cancer (NSCLC) who were treated with ICIs between February 2016 and April 2018. Patients were divided into two groups according to the change rate of the psoas major muscle area (PMMA) at the L2–L3 position and investigated the correlation between the change rate of the PMMA and the efficacy of ICIs was investigated. The objective response and disease control rates were lower in patients with sarcopenia than in those without sarcopenia. Patients with sarcopenia exhibited a significantly shorter median progression-free survival (PFS) than non-sarcopenia patients. Moreover, focusing on good Eastern Cooperative Oncology Group performance status patients, sarcopenia patients showed a shorter PFS than non-sarcopenia patients. Patients with sarcopenia are associated with poor outcomes for immunotherapy among those with advanced NSCLC, based on retrospective analysis. Further research is needed to validate the clinical biomarkers involved in ICI responders.
نوع الوثيقة: text
وصف الملف: application/pdf
اللغة: English
العلاقة: Oncology; https://dx.doi.org/10.3390/jcm8040450Test
DOI: 10.3390/jcm8040450
الإتاحة: https://doi.org/10.3390/jcm8040450Test
حقوق: https://creativecommons.org/licenses/by/4.0Test/
رقم الانضمام: edsbas.B3900341
قاعدة البيانات: BASE